U.S. Markets closed

Co-Diagnostics, Inc. to Expand Technology Licensing Model After Patent Issuance

NEW YORK CITY, NEW YORK / ACCESSWIRE / October 16, 2018 / The CoPrimer™ platform technology created by Co-Diagnostics, Inc. (CODX), a molecular diagnostics company that uses this unique, proprietary platform in the development of their own molecular diagnostic tests, has been granted patent protection by the United States Patent and Trademark Office, and is now being offered under license agreements with manufacturers and developers of molecular diagnostics in a broad array of industry segments.

Once protected by patents, polymerase chain reaction ("PCR") technology can safely be licensed for use by companies that use PCR to design their own diagnostic or research products. Examples of such technology include Roche's TaqMan® probes (RHHBY), LNA® technology by Santaris Pharma, Scorpions® Probes by Sigma-Aldrich (acquired by Merck, MRK) and SYBR® Green, produced by a wholly-owned subsidiary of Thermo Fisher Scientific (TMO). With some recent reports estimating the size of the PCR diagnostics industry alone to reach over $7 billion within the next several years, Co-Diagnostics feels that the ability to monetize its technology in this space has never been more important, nor more valuable, which is now possible following the issuance of the CoPrimer patent.

The patented structure of the CoPrimer molecule has been shown to enhance the output of PCR molecular diagnostic tests by dramatically minimizing the false positive test results that are often caused by traditional primer molecules, making the technology ideal for a wide array of PCR applications. Co-Diagnostics anticipates that the licensing market for their technology includes applications for infectious diseases, SNP/SNV detection, agricultural and food supply chain uses, liquid biopsy, and next generation sequencing.

Companies and laboratories interested in learning more about licensing CoPrimers to design better, higher-performing PCR applications can contact the company at: info@codiagnostics.com.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Visit us here: www.codiagnostics.com

About BDA International, Inc.:

BDA International is an independent global Investor Relations firm offering a wide range of IR-related analysis, research and advisory services. In particular, we provide strategic action plans, and investor/market perception studies to help entities improve communication with customers and investors and increase their visibility. BDA International is responsible for the content of the foregoing release.

Forward-Looking Statements:

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company's liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company's products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company's balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Investor Relations Contact:

BDA International



SOURCE: Co-Diagnostics, Inc.